Brokerages Set Medpace Holdings, Inc. (NASDAQ:MEDP) Price Target at $486.67

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have received an average rating of “Hold” from the fifteen analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $486.6667.

MEDP has been the subject of a number of analyst reports. Mizuho set a $582.00 price objective on shares of Medpace in a report on Wednesday, February 11th. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and cut their target price for the stock from $462.00 to $419.00 in a report on Wednesday, February 18th. Barclays raised shares of Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 price target on the stock in a research report on Friday, March 6th. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective for the company in a research report on Friday, February 13th. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th.

Medpace Trading Up 1.5%

NASDAQ:MEDP opened at $450.41 on Friday. Medpace has a 1-year low of $250.05 and a 1-year high of $628.92. The firm has a market capitalization of $12.78 billion, a price-to-earnings ratio of 29.44, a PEG ratio of 2.16 and a beta of 1.44. The business’s 50-day moving average price is $523.62 and its two-hundred day moving average price is $539.41.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.49. The company had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company’s revenue for the quarter was up 32.0% compared to the same quarter last year. During the same period in the previous year, the company earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts predict that Medpace will post 12.29 earnings per share for the current year.

Institutional Investors Weigh In On Medpace

Several large investors have recently modified their holdings of MEDP. Quent Capital LLC acquired a new position in shares of Medpace in the 3rd quarter valued at approximately $25,000. Optiver Holding B.V. bought a new stake in Medpace during the 3rd quarter worth approximately $27,000. Geneos Wealth Management Inc. raised its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the period. Steigerwald Gordon & Koch Inc. acquired a new stake in Medpace during the 4th quarter worth approximately $30,000. Finally, Elyxium Wealth LLC bought a new position in Medpace in the fourth quarter valued at approximately $30,000. 77.98% of the stock is currently owned by institutional investors.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.